GT Medical Technologies has raised a $45M Series C funding round to develop therapies for patients with brain tumors.
Gilde Healthcare Partners led the round.
GT Medical aims to use the funding round to commercialize its GammaTile Therapy. The latter is an FDA-approved therapy for patients with operable brain tumors.
- GammaTile Therapy is implanted after the brain tumor removal surgery is completed, with the goal of helping to eliminate brain tumor cells through radiation before they can replicate.
- GammaTile Therapy targets tumor cells while preserving brain tissue.
- The company began its operations in 2020, while its GammaTile solution is used in over 80 hospitals across the U.S.
- MVM Partners, MedTech Venture Partners, and BlueStone Venture Partners also participated in the funding.
- The company is based in Tempe, Arizona.
